Trade Report: Today, NxStage Medical Inc. (NXTM) Given Average Recommendation of “Buy” from Analysts

Today, NxStage Medical Inc. (NXTM) Given Average Recommendation of “Buy” from Analysts

Shares of NxStage Medical Inc. (NASDAQ:NXTM) have been assigned an average recommendation of “Buy” from the eight analysts that are currently covering the stock. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $25.67.

NXTM has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research note on Tuesday, August 9th. BTIG Research reaffirmed a “buy” rating and issued a $29.00 target price on shares of NxStage Medical in a research note on Sunday, August 7th. Jefferies Group boosted their target price on shares of NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, August 5th. Canaccord Genuity lifted their price target on shares of NxStage Medical from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. Finally, Northland Securities set a $25.00 price target on shares of NxStage Medical and gave the stock a “buy” rating in a research report on Thursday, September 15th.

NxStage Medical (NASDAQ:NXTM) traded up 3.13% during midday trading on Friday, reaching $26.03. 254,923 shares of the company’s stock were exchanged. The stock’s market cap is $1.69 billion. NxStage Medical has a 1-year low of $13.49 and a 1-year high of $26.83. The firm’s 50-day moving average is $24.31 and its 200 day moving average is $22.52.

In related news, SVP Winifred L. Swan sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $25.51, for a total transaction of $76,530.00. Following the completion of the transaction, the senior vice president now owns 14,973 shares in the company, valued at $381,961.23. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeffrey H. Burbank sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $25.51, for a total transaction of $191,325.00. Following the transaction, the chief executive officer now owns 905,116 shares of the company’s stock, valued at approximately $23,089,509.16. The disclosure for this sale can be found here. Corporate insiders own 4.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. boosted its position in shares of NxStage Medical by 1.1% in the third quarter. Principal Financial Group Inc. now owns 14,037 shares of the medical device company’s stock worth $351,000 after buying an additional 156 shares in the last quarter. Menta Capital LLC boosted its position in NxStage Medical by 1.0% in the second quarter. Menta Capital LLC now owns 37,180 shares of the medical device company’s stock valued at $806,000 after buying an additional 380 shares during the period. State Board of Administration of Florida Retirement System boosted its position in NxStage Medical by 1.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 49,876 shares of the medical device company’s stock valued at $1,081,000 after buying an additional 640 shares during the period. BlackRock Advisors LLC boosted its position in NxStage Medical by 1.5% in the second quarter. BlackRock Advisors LLC now owns 57,870 shares of the medical device company’s stock valued at $1,255,000 after buying an additional 865 shares during the period. Finally, Nationwide Fund Advisors boosted its position in NxStage Medical by 2.4% in the second quarter. Nationwide Fund Advisors now owns 41,692 shares of the medical device company’s stock valued at $904,000 after buying an additional 968 shares during the period. Hedge funds and other institutional investors own 98.86% of the company’s stock.

Related posts

Leave a Comment